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Abstract
Background: The chemokine (C-C motif) ligand 2 (CCL2) is a monocyte chemoattractant protein that mediates
macrophage recruitment and migration during peripheral and central nervous system (CNS) inflammation.
Methods: To determine the impact of CCL2 in inflammation in vivo and to elucidate the CCL2-induced polarization
of activated brain microglia, we delivered CCL2 into the brains of wild-type mice via recombinant adeno-associated
virus serotype 9 (rAAV-9) driven by the chicken β-actin promoter. We measured microglial activation using
histological and chemical measurement and recruitment of monocytes using histology and flow cytometry.
Results: The overexpression of CCL2 in the CNS induced significant activation of brain resident microglia. CD45
and major histocompatibility complex class II immunoreactivity significantly increased at the sites of CCL2
administration. Histological characterization of the microglial phenotype revealed the elevation of “classically
activated” microglial markers, such as calgranulin B and IL-1β, as well as markers associated with “alternative
activation” of microglia, including YM1 and arginase 1. The protein expression profile in the hippocampus
demonstrated markedly increased levels of IL-6, GM-CSF and eotaxin (CCL-11) in response to CCL2, but no changes
in the levels of other cytokines, including TNF-α and IFN-γ. Moreover, real-time PCR analysis confirmed increases in
mRNA levels of gene transcripts associated with neuroinflammation following CCL2 overexpression. Finally, we
investigated the chemotactic properties of CCL2 in vivo by performing adoptive transfer of bone marrow–derived
cells (BMDCs) isolated from donor mice that ubiquitously expressed green fluorescent protein. Flow cytometry and
histological analyses indicated that BMDCs extravasated into brain parenchyma and colabeled with microglial
markers.
Conclusion: Taken together, our results suggest that CCL2 strongly activates resident microglia in the brain. Both
pro- and anti-inflammatory activation of microglia were prominent, with no bias toward the M1 or M2 phenotype
in the activated cells. As expected, CCL2 overexpression actively recruited circulating monocytes into the CNS. Thus,
CCL2 expression in mouse brain induces microglial activation and represents an efficient method for recruitment of
peripheral macrophages.
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Background
Cerebral inflammation involving activation of resident
glial cells, release of soluble mediators, such as cytokines
and chemokines, and infiltration of peripheral bone mar-
row–derived myeloid cells (BMDCs) is a process that oc-
curs throughout the course of many neurodegenerative
diseases. The chemokine (C-C motif ) ligand 2 (CCL2)
protein (also known as macrophage chemoattractant
protein 1, or MCP-1) is well-recognized for its ability to
mediate macrophage recruitment and migration to sites
of inflammation in rheumatoid arthritis, multiple scler-
osis, traumatic brain injury, stroke and Alzheimer dis-
ease (AD) [1-7]. Transgenic mice that overexpress CCL2
in the central nervous system (CNS) exhibit a robust ac-
cumulation of macrophages and activation of microglia
in the brain [8,9], whereas mice deficient in the CCL2
gene show reduced leukocyte infiltration after auto-
immune encephalomyelitis, traumatic brain injury, spinal
cord injury and HIV-associated dementia [10-12]. In
neurodegenerative diseases such as AD, recent evidence
derived from genetically modified animal models sug-
gests that infiltrating macrophages contribute to reduced
amyloid pathology [13-18]. Other studies have indicated
that CCL2 expression accelerates amyloidosis in an
amyloid precursor protein (APP)/CCL2 bigenic mouse
model, suggesting a different role of CCL2 in resident
microglia and ultimately the AD pathology of these mice
[19]. Also, CCL2 levels are reportedly increased in the
brain, serum and cerebrospinal fluid of AD patients
[20-22], further supporting a central role for this chemo-
kine in neuroinflammation.
The impact of CCL2 on microglial activation and infil-
tration of specific macrophage subsets into the CNS
may be very different in adult vs developing mice.
Hence, in this experiment, we used recombinant adeno-
associated virus (rAAV) to overexpress and distribute
CCL2 in the CNS of adult mice and to investigate the ef-
fect of CCL2 on microglial activation in vivo. Microglia,
the primary immune-competent cells of the CNS,
exhibit many stages of activation and varying morph-
ology [23,24]. Resting microglia exhibit a ramified
morphology and express low levels of many cell surface
immune molecules. Activated microglia exhibit an
amoeboid morphology [25], increased phagocytic ability
and enhanced migratory capacity within the brain, along
with increased expression of cell surface glycoproteins,
including CD45 and major histocompatibility complex
class II (MHCII) [26]. The activation state of microglia is
characterized by two main classes [27]. The “classically
activated” M1 microglial phenotype is characterized by
strong antigen-presenting abilities, proinflammatory
cytokine production and the production of toxic inter-
mediates such as nitric oxide and reactive oxygen spe-
cies. The “alternatively activated” M2 microglia are
involved in tissue repair and wound-healing processes,
are characterized by high levels of arginase expression
and are generated in response to cytokines such as IL-4,
IL-10 and IL-13 [28,29].
Evidence for an essential role of CCL2 in macrophage
activation in disease models such as atherosclerosis and
asthma [5,30,31], together with the observation that
inflammatory stimuli induce its expression, has led to con-
sideration of CCL2 as an inflammatory chemokine. How-
ever, adaptive immunity studies have suggested that CCL2
expression is strongly associated with development of Th2
responses (for example, resistance in Leishmania major
infection) [32] and with enhanced IL-4 and IL-10 secre-
tion by T cells [33,34].
In this experiment, we (1) investigated the role of
rAAV-delivered CCL2 on activation and polarization of
microglia in the CNS microenvironment, (2) performed
histological characterization of various activation states
of microglia expressing M1 vs M2 activation markers
and (3) measured extravasation of bone marrow–derived
monocytes into the CNS in a CCL2-dependent fashion,
without using the radiation required for bone marrow
grafts. Interestingly, introduction of CCL2 via rAAV9
transduction resulted in secretion of cytokines representing
both spectra of microglial activation states. Furthermore,
real-time quantitative PCR demonstrated a dual effect of
CCL2 on gene expression associated with microglial acti-
vation in vivo. We showed that a single chemokine can
affect two very essential pathways, suggesting that CCL2 is
an attractive target in neuroinflammatory diseases.
Methods
Experimental design
Wild-type, nontransgenic 14-month-old mice underwent
intracranial injection of rAAV expressing CCL2 or green
fluorescent protein (GFP), followed by adoptive transfer
of GFP+ BMDCs. Mice were randomly assigned to two
cohorts.
In cohort 1, mice were divided into two groups. The
first group received unilateral, intracranial injections of
rAAV9 vector expressing CCL2 (n =6) in both the right
anterior cortex and right hippocampus. The second
group received identically placed injections of rAAV9-
GFP (control, n = 6). Seven weeks after the intracranial
injections, mice received a single intracardiac injection
of GFP+/CD11b+ bone marrow–derived monocytes (see
below). The mice were killed 24 h later. Tissue from
these animals was utilized for all immunohistochemical
analyses presented in this report.
In cohort 2, mice of the first group received bilateral,
intracranial injections of rAAV9-CCL2 (n = 6) in both
the hippocampus and the anterior cortex for a total of
four injections. The second group received identically
placed injections of rAAV-GFP (n = 6). As described
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above, both groups received adoptive transfer of bone
marrow cells 7 wk later. Half of the brain was collected
and utilized for flow cytometry, and tissue from the
other half of the brain was utilized for RT-PCR or multi-
plex assays as described below.
Studies conducted at our laboratory and others have
demonstrated the capabilities of rAAV serotype 9 to
transduce neurons within specific regions in the mouse
brain [35,36]. rAAV9 has high transduction efficiency
and drives robust gene expression. Gene expression oc-
curs as early as 1 wk in vitro and in vivo [37,38] and per-
sists for more than 9 mo in mouse brain [35]. Therefore,
rAAV9 is a preferred candidate to deliver CCL2/GFP
in vivo. We chose to examine microglial activation and
monocyte recruitment 7 wk after viral injection to allow
strong expression and to provide time for recovery from
the intracranial injection.
A transgenic line ubiquitously expressing GFP was
used as the source of bone marrow–derived monocytes
(C57BL/6-Tg (UBC-GFP) 30Scha/J; The Jackson Labora-
tory, Bar Harbor, ME, USA). These transgenic mice
express GFP under the direction of the human ubiquitin
C promoter. All mice maintained in the University of
South Florida Health Byrd Alzheimer Institute animal
facility follow the according to guidelines established by
“Guide for the care and use of laboratory animals” and
are approved by IACUC.
CCL2-AAV9 preparation
The CCL2 clone was generated from mouse cDNA and
amplified using PCR with primers 5′- GAGACCGGT
CCACCATGCAGGTCCCTGTCATGCTTC-3′ and 5′-
GAGGCTAGCCTAGTTCACTGTCACACTGGTCAC
TCC-3′. CCL2 was cloned into the AgeI and NheI sites of
the rAAV vector pTR2-RMCS under the control of the
hybrid cytomegalovirus chicken β-actin promoter. This
vector also expresses red fluorescent protein (RFP) under
the control of the thymidine kinase promoter and AAV2
terminal repeats. rAAV serotype 9 virus was generated
using pAAV9 and pXX6 in HEK293 cells as described
previously [39].
Intracranial injections
The injection procedures were performed using a
convection-enhanced delivery method described previ-
ously [39]. Briefly, mice were anesthetized with 1.5%
isoflurane in 100% oxygen and secured into a stereotac-
tic apparatus. Each animal was given an injection unilat-
erally (cohort 1, n = 6) or bilaterally (cohort 2, n = 6)
with 2 μl of rAAV9-CCL2 (7 × 1012 vector genome (vg/ml)
or 2 μl of rAAV9-GFP (control, n = 6 per cohort) into both
cortex and hippocampus. The coordinates of injection
were as follows: hippocampus (from bregma) anteroposter-
ior –2.7 mm, lateral ±2.7 mm, dorsoventral −3.0 mm;
cortex, anteroposterior (from bregma) +2.2 mm, lat-
eral ±1.7 mm, dorsoventral −3.0 mm. A microsyringe
injector and controller (Stoelting, Wood Dale, IL,
USA) were used to inject 2 μl of virus at a constant
rate of 2.5 μl/min in each placement. The needle was
kept in place for 1 min after injection and then raised
slowly. Mice were allowed to recover for 7 wk.
Adoptive transfer of bone marrow–derived cells
CD11b+ cells were collected as previously described
[40]. Briefly, transgenic mice ubiquitously expressing
GFP were injected with a euthanasia solution, and their
femurs and tibias were removed aseptically. Femoral
and tibial marrow cavities were flushed with RPMI
1640 media containing fetal bovine serum and HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH
7.4, using a 25-gauge needle. Single-cell suspensions were
prepared by repeat pipetting, and the cell preparations
were passed through a 70-μm nylon mesh to remove cell
debris. Red blood cells (RBCs) were removed by exposure
to 3 ml of RBC lysis buffer (5 min, room temperature)
before dilution in cold phosphate-buffered saline (PBS).
Cells were centrifuged, washed twice in RPMI 1640
and counted using a hemocytometer. CD11b+ cells
were enriched using Miltenyi Biotec’s LS columns and
MidiMACS magnet (Auburn, CA, USA) following the
manufacturer’s instructions. Briefly, 70 million to 100
million bone marrow cells from GFP transgenic mice
were suspended in 2.7 ml of PBS and 0.5% bovine serum
albumin and incubated for 15 min, together with CD11b
antibody conjugated to magnetic microbeads at 4°C. The
cell suspension was applied to the supplied column in a
magnetic field, and the CD11b+ fraction was separated
from the unlabeled cells by washing three times with
3 ml of buffer. The column was separated from the
magnet, and CD11b+ cells were collected. The purity
of immunomagnetically separated cells was measured
using a FACSCalibur flow cytometer (BD Biosciences,
San Jose, CA, USA). Cells were then counted, and 5 × 106
freshly isolated CD11b+ (GFP+) cells were resuspended in
100 μl of saline and injected into the left heart ventricles
of CCL2- and rAAV9-GFP transduced mice of both
cohort 1 and cohort 2.
Tissue collection and histochemical procedures
Twenty-four hours after adoptive transfer, mice were
killed and perfused transcardially with PBS. The brains
from cohort 1 were removed and immersed in freshly
prepared 4% paraformaldehyde in 100 mM phosphate
buffer, pH 7.4, prior to being cryoprotected in a series of
sucrose solutions, frozen and sectioned in the horizontal
plane at 25 μm using a sliding microtome. Every eighth
section was collected with a 50-μm thickness for stereol-
ogy. Sections were stored at 4°C in Dulbecco’s PBS and
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0.05% azide for immunohistochemistry. Immunohisto-
chemistry was performed on free-floating sections as
previously described [41]. A series of six sections from
each animal were incubated with each primary antibody
overnight at room temperature, then incubated in the
biotinylated secondary antibody (2 h) followed by incu-
bation for 1 h in avidin-biotin complex (VECTASTAIN
Elite ABC kit; Vector Laboratories, Burlingame, CA,
USA). Color development was performed using 1.4 mM
diaminobenzidine with 0.03% hydrogen peroxide in PBS
for 5 min. The following primary antibodies were used
for immunohistochemistry: CCL2 (rat anti-CCL2; R&D
Systems, Minneapolis, MN, USA), YM1 (rabbit anti-
YM1; Stem Cell Technologies, Vancouver, BC, Canada),
arginase 1 (chicken anti-Arg-1; generous gift from Dr
Sidney Morris), IL-1β (rat anti-IL-1β; R&D Systems),
S100A9 (goat anti-S100A9, R&D Systems), GFP (chicken
anti-GFP; Abcam, Cambridge, MA, USA), CD45 (rat
anti-mouse; AbD Serotec, Raleigh, NC, USA), MHCII
(rat anti-MHCII; BD Biosciences). Immunofluorescence
labeling was performed as follows. After incubation with
the primary antibody, the free-floating sections were incu-
bated for 2 h with the appropriate fluorophore-coupled
secondary antibodies: Alexa Fluor 594 (1:1,500), Alexa
Fluor 488 (1:1,500) or Alexa Fluor 405 (1:1,500; Invitrogen,
Grand Island, NY, USA). Possible lipofuscin artefacts
were quenched by treating slides with 3% Sudan Black
B stain as described previously [42]. Sections were rinsed
in Dulbecco’s PBS and coverslipped with VECTASHIELD
HardSet Mounting Medium with or without 4′,6-
diamidino-2-phenylindole (Vector Laboratories).
For cohort 2, the left hemisphere was dissected into
brain regions and snap-frozen for biochemical ana-
lyses including RT-PCR and multiplex assay (see
below). The right-half brain was immersed in Hanks’
balanced salt solution containing 0.2% collagenase
type 3 (Roche Diagnostics, Mannheim, Germany) and
3.0 U/ml purified dispase (Worthington Biochemical
Corp, Lakewood, NJ, USA) for 45 min at 37°C followed by
incubation with 40 μg/ml DNase (Sigma, St Louis, MO,
USA) for an additional of 15 min at 37°C. After a series of
triturations, the cell suspension was mixed with physio-
logical 90% Percoll solution and centrifuged as described
previously [43]. Brain cells in suspension were then incu-
bated with fluorescein isothiocyanate (FITC)-labeled anti-
body to GFP (1 mg/ml) (Abcam) or with isotype-matched
control antibody for 30 min on ice. GFP fluorescence in-
tensity was measured using a FACSCalibur flow cytometer
and analyzed using BD CellQuest Pro software (BD
Biosciences).
Image analysis and stereology
Immunohistochemistry was quantified using Image-Pro
Plus software (Media Cybernetics, Rockville, MD, USA).
Segmentation of positive stain was performed using RGB
identification and was held constant throughout the immu-
nohistochemical analysis. The hippocampus was manually
circumscribed and the percentage area of immunostaining
was calculated in each hemisphere. A similarly sized area at
the site of the rAAV placement in the anterior cortex was
analyzed separately. Values obtained from all sections from
a single mouse were averaged to represent a single value
for that animal (per brain region and per hemisphere).
Stereological analysis was performed as previously
described [44]. We used a rare event protocol in which
all positive cells in the region analyzed were counted as
follows after confirming they were not visible on the upper
surface of the section: N = (number of cells counted) ×
(1/ssf ) × (1/asf ) × (1/tsf ), where ssf is the section
sampling fraction (that is, one-eighth of the total sec-
tions used), asf is the area sampling fraction (in this case,
the entire region rather than a dissector, thus asf = 1) and
tsf is the thickness sampling fraction (tsf = 1).
Multiplex chemokine/cytokine assay
Snap-frozen left hippocampi from the animals in cohort
2 were homogenized in radioimmunoprecipitation assay
buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
ethylenediaminetetraacetic acid, 1% Triton X-100, prote-
ase inhibitor cocktail and phosphatase inhibitor cocktail
I and II; Sigma). The protein concentration of each
sample was measured using the Bradford protein assay
(Bio-Rad Laboratories, Hercules, CA, USA) and adjusted
to 4.5 mg/ml. The concentrations of IL-1β, IL-4, IL-6,
IL-10, IL-12p70, IL-13, IL-17, interferon γ (IFN-γ),
tumor necrosis factor α (TNF-α), CCL2, eotaxin 1
(CCL11) and granulocyte macrophage colony-stimulating
factor (GM-CSF) were measured using the mouse cyto-
kine/chemokine panel (MILLIPLEX MAP kit; Millipore,
Billerica, MA, USA) according to the manufacturer’s
protocol. In brief, the Bio-Plex Suspension Array System
(Bio-Rad Laboratories) was calibrated using CAL2 with
the high PMT setting of the Bio-Plex calibration kit, and
standard sample preparation was performed according to
the manufacturer’s directions. The filter plate was
prewetted with wash buffer and vacuum-filtered before
adding standard, control or study samples to the appropri-
ate wells. Mixed capture beads were then added to each
well, and plates were incubated overnight at 4°C with shak-
ing. After two washes, 25 μl of detection antibody were
added to each well, incubated for 1 h at room temperature
and then treated with 25 μl of streptavidin-phycoerythrin
for 30 min at room temperature. The plate was washed
twice, and 150 μl of the Bio-Plex sheath fluid assay buffer
were added to each well and read using the Bio-Plex
Suspension Array System software (Bio-Rad Laboratories)
per the kit instructions. The concentration of each analyte
was calculated according to the standard curve.
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Quantitative real-time PCR
Total RNA from mouse anterior cortex (cohort 2) was
isolated using the RNeasy kit (QIAGEN, Valencia, CA,
USA) and reverse-transcribed using SuperScript III re-
verse transcriptase (Invitrogen, Carlsbad, CA, USA).
Gene transcript functions included in this study (Table 1)
have been reported previously [45-58] and were recently
published by investigators at our laboratory [59].
QuantiTect primers for each gene (Arg-1: cat. no.
QT00134288, Retnla: cat. no. QT00254359, Marco: cat.
no. QT00102004, S100A8: cat. no. QT01749958, S100A9:
cat. no. QT00105252, Timp1: cat. no. QT00996282,
Sirpβ: cat. no. QT02332008, Chi3l3: cat. no. QT00108829,
iNOS: cat. no. QT00100275, CCL24: cat. no. QT00
126021, CCL26: cat. no. QT01559481, EAR1: cat. no.
QT00261303, EAR2: cat. no. QT00265965, EAR11:
cat. no. QT00266959, IGF-1: cat. no. QT00154469) were
purchased and used for SYBR Green-based real-time RT-
PCR (QIAGEN). qPCR was performed as follows: one
cycle at 95°C for 5 min, one cycle at 95°C for 30 s and one
cycle at 60°C for 1 min followed by 40 amplification cycles
at 95°C for 30 s. The melting curve readings were
performed every 1°C at 56°C to 99°C, holding for 1 s be-
tween readings. The DNA Opticon 2 System for Real-
Time PCR Detection Version 4.3 (Bio-RadLaboratories)
was used to detect the amplification products. None of the
primers demonstrated more than one peak of fluorescence
in melt curve analysis. The standard curve was calculated
by plotting the cycle threshold change (ΔCt) against the
log nanogram quantity of RNA added [60]. Linear regres-
sion was performed, and the slope relating ΔCt to log
nanograms of RNA was calculated and converted to a
mass quantity of standard RNA. The mass values for the
genes of interest were then normalized to GAPDH mRNA
to determine the fold change in mRNA expression relative
to the standard RNA pool. A ΔCt cut-off greater than 36
cycles was considered nondetectable (ND).
Statistical analysis
Statistical analyses were performed using Student’s t-test
or one-way analysis of variance (ANOVA) followed by
Fisher’s least significant difference post hoc means com-
parison test using StatView version 5.0 software (SAS
Institute Inc, Cary, NC, USA). Graphs were generated
using GraphPad Prism 4.0 software (GraphPad Software,
La Jolla, CA, USA).
Results
CCL2 expression was exacerbated in rAAV9-CCL2
injected mice
To assess the role of CCL2 in activation of resident brain
glial cells and infiltration of peripheral macrophages, we
constructed a rAAV-9 pTR2-CCL2 vector (Figure 1A).
The PCR product of RFP and mouse CCL2 is shown in
Figure 1B (650 bp and 440 bp, respectively). Fourteen-
month-old mice were injected with either rAAV9-CCL2
or rAAV9-GFP viral particles, unilaterally (cohort 1, see
Methods) or bilaterally (cohort 2) in both the hippocam-
pus and the cortex. CCL2 protein levels were measured
in the hippocampal tissue of cohort 2 animals at 7 wk
after the injection by using the MILLIPLEX MAP Multi-
plex assay kit (Figure 1C). Basal levels of CCL2 in
rAAV9-GFP-injected animals were in the low range
(0.13 ng/ml); however, as expected, CCL2 expression
was significantly higher in the hippocampi of rAAV9-
CCL2-injected animals (406 ng/ml). In addition, we
confirmed expression of CCL2 by immunohistochemi-
cal staining (Figure 2). CCL2 expression was observed
throughout the ipsilateral hippocampus and cortex of ani-
mals injected with rAAV9-CCL2 (Figures 2B and 2D). As
expected, we did not detect CCL2 immunoreactivity in
the mice injected with rAAV-GFP (Figures 2A and 2C) or
in the contralateral hemisphere (not shown). The area oc-
cupied by CCL2 immunoreactivity was significantly larger
in mice injected with rAAV-CCL2 than in mice injected
with rAAV-GFP (Figures 2E and 2F).
CCL2 is chemotactic after adoptive transfer of
CD11b-positive bone marrow–derived cells
To investigate the role of CCL2 in the chemotaxis of
peripheral myeloid cells in the brain, we systemically
injected CD11b+ BMDCs isolated from donor mice and
monitored their uptake into the CNS. The BMDCs ubi-
quitously overexpressed GFP. Twenty-four hours before
tissue collection, 5 million CD11b+/GFP cells (mostly
monocytes) in a volume of 100 μl were injected into re-
cipient mice previously treated with rAAV9-CCL2 or
rAAV9-GFP (cohort 1 or 2). Using both histological
evaluation and flow cytometry, we confirmed the migra-
tion of these cells into the CNS of CCL2-injected mice
(Figure 3). To identify the extravasation and distribution
of GFP+ cells, we first performed immunohistochemical
staining for GFP using sections from rAAV9-CCL2-
injected animals (cohort 1). Our data showed that GFP+
BMDCs were located mainly in the parenchyma of the
ipsilateral hippocampus and cortex as well as in the peri-
vascular area (Figures 3A through 3D). Furthermore, we
used unbiased stereology [44] to count CD11b+/GFP+
labeled cells in the CNS after overexpression of CCL2
(Figure 3E). More GFP+ cells were counted in the ipsi-
lateral hippocampus compared to the ipsilateral cortex.
GFP+ cells in the rAAV-GFP-injected mice could not be
counted, because there was marker overlap between the
rAAV-GFP and the GFP+ monocytes.
In addition, we used flow cytometry (Figures 3F and
3G). The right hemispheres of animals in cohort 2 were
processed to isolate CNS single-cell suspensions from
the CCL2- and GFP-injected mouse brains as described
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Table 1 Expression of gene transcripts in mice overexpressing CCL2 compared with control mice




NM_010766 Marco Macrophage receptor with collagenous structure 0.6 ↓ P < 0.004 Scavenger receptor expressed in a subset of macrophages [39]
NM_001002898 Sirpβ Signal-regulatory protein β 17.13↑ P < 0.002 Cytoskeleton rearrangement, counterregulates proinflammatory
mediators, phagocytosis [40]
NM_013650 S100A8 S100 calcium-binding protein A8 (calgranulin A) 3.1↑ P < 0.03 Calcium-binding protein involved in innate immune response [41]
NM_009114 S100A9 S100 calcium-binding protein A9 (calgranulin B) ND Forms heterodimeric protein complex with S100A8 [43,44]
NM_011593 Timp1 Tissue inhibitor of metalloproteinase 1 ND Inhibitory role against most matrix metalloproteinases, promotes
cell proliferation [45,46]
NM_010927 iNOS Nitric oxide synthase, inducible ND Immune defense against pathogens, induces inflammation and
oxidative stress [47]
NM_001111274 IGF-1 Insulin-like growth factor 1 ND Mammalian growth and development [48]
M2 genes
NM_007482 Arg1 Arginase 1, liver 2.4↑ P < 0.006 Arginine and proline metabolism [49]
NM_007695 Chi3l3 Chitanase 3-like 3 2.7↑ P < 0.003 Expressed in myeloid precursor cells, involved in inflammation
(alternative activated macrophages) [27]
NM_020509 Retnla Resistin-like α ND Alternatively activated macrophages and tissue repair [50]
Chemotactic (M2) genes
NM_019577 CCL24 C-C motif chemokine 24 1.7↑ P < 0.04 Chemotaxis [51]
NM_001013412 CCL26 C-C motif chemokine 26 ND Induces migration of eosinophils macrophages and basophils [52]
NM_007894 EAR1 Eosinophil-associated, ribonuclease A family, member 1 ND RNase activity, chemotactic for eosinophils, alveolar macrophages
[53]
NM_007895 EAR2 Eosinophil-associated, ribonuclease A family, member 2 3.8↑ P < 0.02 RNase activity, chemotactic for eosinophils, alveolar macrophages
[53]
NM_053113 EAR11 Eosinophil-associated, ribonuclease A family, member 11 ND RNase activity, chemotactic for eosinophils, alveolar macrophages
[53]
qRT-PCR was performed in anterior cortex brain homogenate from animals injected with rAAV9-GFP (n = 6) and rAAV9-CCL2 (n = 6). RNA (10 ng/μl) of each sample was used for cDNA synthesis. The mass values for
the genes of interest were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA to determine fold change in mRNA expression relative to the standard RNA pool. The fold-change values for
samples in rAAV9-GFP-treated vs rAAV9-CCL2-treated animals were analyzed and presented as M1- and M2-related gene transcript expression. A cycle threshold change (ΔCt) greater than 36 cycles was considered
nondetected (ND). Statistical analyses were performed using Student’s t-test (n = 6). P values were specified for each gene. ↑ and ↓ represent significant increases or decreases from control mice at P < 0.05. ND, not




















previously [43]. This method resulted in collection of cells
based on their forward-scatter parameter. The isolated
cells were stained with FITC-conjugated anti-GFP anti-
body. No GFP+ cells were recovered from animals treated
with rAAV-GFP, suggesting that transfected neurons are
not recovered using this methodology. The GFP+ popula-
tion (green) identified by the increased FITC intensity
(boxed area) was significantly enriched as a proportion of
the CNS cells in CCL2-injected mice compared with con-
trols (19% vs 0.3%, respectively) (Figure 3F). Analysis of
2,000 events from each brain preparation revealed that
GFP+ cells found in the CCL2-injected mice were signifi-
cantly higher than in the control animals (Figure 3G).
CCL2 induces CD45 microglial activation
The contribution of CCL2 in regulating leukocyte accu-
mulation in the CNS following CCL2 transduction was
assessed by immunohistochemistry. To verify the effect
of CCL2 expression on activation of microglia, immuno-
reactivity of brain tissue for CD45 + microglia was mea-
sured in rAAV9-CCL2 and rAAV9-GFP injected mice.
Accumulation of mononuclear cells positive for CD45 in
the brain 7 weeks post rAAV injection were observed in
both hippocampus and cortex of CCL2 overexpressing
animals (Figure 4). CD45 mononuclear cells occupied
areas around the injection site and in the blood vessels
lining ipsilateral hippocampus (arrow, Figure 4D, E
and F). Following CCL2 overexpression, microglia
were activated and acquired a ramified morphology
throughout both cortex and hippocampus (Figure 4B,
D, G and H). CD45+ microglia levels were signifi-
cantly higher in the parenchyma of the ipsilateral
hemisphere in CCL2 injected mice compared to the
GFP control mice. When quantified using image ana-
lysis (percent positive area), we found that CD45 ex-
pression was significantly increased in cortex and in
the hippocampus of CCL2 overexpressing mice (Figure 4I
and J). Microglia from rAAV9-GFP injected mice remained
negative for CD45 expression in both regions of inter-
est (Figure 4A, C and I-J).
Microglia exhibit enhanced expression of cell-surface
MHCII following CCL2 overexpression
To further characterize the effect of CCL2 on brain micro-
glial activation and phenotype surface molecules affected
by this stimulus, we investigated the expression of MHCII
(Figure 5). MHCII expression is detected on activated
brain resident microglia, as well as on infiltrating imma-
ture myeloid cells, which can differentiate into MHCII+
macrophages [61]. CCL2 increased the accumulation of
cells that were highly immunoreactive for MHCII in the
ipsilateral cortex and hippocampi of rAAV-CCL2-injected
animals (Figures 5B and 5D through 5H). These MHCII
cells presented various morphologies, including the rami-
fied morphology typical of activated microglia (higher
magnification shown in Figures 5E and 5H, arrows), al-
though other cells had a more rounded morphology con-
sistent with perivascular macrophages (Figures 5F and 5G,
arrowheads). We observed that MHCII+ round cells accu-
mulated near the sites of injection, such as the dentate
Figure 1 Production of rAAV-CCL2 construct and documentation of CCL2 overexpression in mouse tissue. (A) Schematic representation
of pTR2-GMCS vector construct used to express chemokine (C-C motif) ligand 2 (CCL2). Chicken β-actin (CBA) promoter was used to drive the
expression of CCL2, and RFP expression was driven by HSV thymidine kinase (HSV-tk) promoter. Construct vector was flanked by two terminal
repeats (TR). (B) PCR product of the expected size for CCL2 (440 bp). (C) Expression of CCL2 (mean ± SEM, ng/ml) in the hippocampus 7 wk after
injection of animals with either rAAV9-CCL2 or rAAV9-GFP (**P < 0.01, n = 6).
Selenica et al. Journal of Neuroinflammation 2013, 10:86 Page 7 of 17
http://www.jneuroinflammation.com/content/10/1/86
gyrus in the hippocampus, blood vessels in the hippocam-
pus and vessels descending from the pia in the cortex
(Figures 5B and 5D, arrows). We were unable to detect
MHCII immunoreactivity in the brain microglia of ani-
mals transduced with rAAV9-GFP, except in the immedi-
ate vicinity of the injection site (Figures 5A and 5C).
Quantification of MHCII expression by image analysis
showed significantly higher immunoreactivity in both the
cortex and the hippocampus of rAAV-CCL2-treated mice
vs control mice (Figures 5I and 5J).
CCL2 overexpression leads to induction of classical
microglial activation (M1 state)
To this point, our data suggested that CCL2 overexpression
can generate activation of microglia using markers such as
CD45 and MHCII. CCL2 has been reported to be a
pro-inflammatory chemokine, with its primary effect
on the innate immune system via chemotaxis of
monocytes. However, a few studies have reported that
CCL2 affects the adaptive immune system by Th1/Th2
polarization [32,33]. Therefore, we investigated the effect
of increased CCL2 levels on the CNS microglia activation
stages, also referred to as M1/M2 activation. To
understand the effect of CCL2 on polarization of
brain microglia, we evaluated markers of microglial
classical activation (Figures 6A through 6F). Both IL-1β
and calgranulin B (S100A9) are proinflammatory pro-
teins that are associated with classical activated microglia.
S100-A9 is an inflammatory marker protein expressed al-
most exclusively in myeloid cells [62]. We found that
CCL2 induced high levels of S100-A9 expression and that
S100-A9 positive cells were prominently located around
the site of injection. The positive cells were exclusively of
the rounded mononuclear phenotype (Figure 6B and C).
These findings suggest that the S100A9-expressing cells
did not transform into an activated phenotype, in spite of
the CCL2 stimulus, or that the observed mononuclear
phenotype represents the newly recruited cells responding
to the CCL2 stimulus [63]. Immunohistochemical evalu-
ation revealed IL-1β positive microglia, found in the par-
enchyma of the ipsilateral hemisphere of CCL2 injected
mice. The parenchymal IL-1β positive cells displayed
Figure 2 CCL2 distribution and expression in the brain. Immunohistochemical staining for CCL2 was performed. (A) through (D) Overall
distribution of CCL2 in the brains of animals injected with rAAV9-GFP and rAAV9-CCL2. Photomicrographs represent the expression of CCL2 in the
ipsilateral (injected) hemisphere in GFP control (A) and (C) and CCL2 animals (B) and (D). Higher magnification shows neuronal localization of CCL2
expression (insets). (E) and (F) present the means ± SEM of percentage positive area of immunostaining for CCL2 in the cortex and hippocampus,
respectively. Scale bar represents 200 μm (20 μm for insets). Statistical analyses were performed using Student's t-test (**P < 0.01, n = 6 per group).
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predominantly a ramified/activated phenotype (Figure 6E)
although rounded mononuclear cells were observed in the
vicinity of blood vessel and meninges (Figure 6F). Brain tis-
sue from control animals did not stain positively for any of
the M1 markers (Figures 6A and 6D).
CCL2 overexpression induces expression of alternative
activation (M2) microglia markers and regulates cytokine
expression
To determine whether CNS overexpression of CCL2 al-
ters microglial activation toward an alternative activation
(M2) state, we performed histological evaluations using
arginase 1 (Arg-1) and chitinase 3-like-3 (YM1) as spe-
cific markers for the M2-activated microglia [64]. The
pattern of inflammatory cells was different in rAAV9-
CCL2-injected mice than in rAAV-GFP-injected control
mice (Figure 6). The microglia of CCL2-overexpressing
mice were immunoreactive for the Arg-1 marker in the
ipsilateral hemisphere, and the Arg-1+ microglia showed
a range of morphologies (Figures 6H and 6I). For in-
stance, we observed Arg-1+ microglia displaying a rod-
shaped phenotype (Figure 6I), whereas Arg-1+ rounded
mononuclear cells were occasionally found in the CCL2
mice (Figure 6H). YM1 represents another alternative
activated microglial cell–surface marker. We found that
CCL2 overexpression induced YM1 expression on brain
microglia, and, overall, YM1+ cells were present in the
regions where overexpression of CCL2 was more abun-
dant. YM1+ microglia displayed equal distribution be-
tween ramified and rounded morphologies in both brain
regions (Figures 6K and 6L). We found that rAAV9-GFP
animals did not show positive immunoreactivity for
any of the alternative activation microglial markers (Fig-
ures 6G and 6J). These results suggest that microglia
adopted the M2 phenotypic characteristics in response to
CCL2 overexpression.
Next, we performed double-immunofluorescence to de-
termine whether infiltrating GFP+ BMDCs colocalized
with markers of activated microglia. We found that some
infiltrating GFP+ cells that extravasated into the paren-
chyma of the CCL2-treated mouse brain colabeled with
YM1 (Figures 7A through 7C) and CD45 (data not shown).
On the other hand, recruited GFP+ cells did not colabel
with MHCII (Figures 7D through 7F). Consequently,
markers currently in use to identify microglia fail to dis-
criminate between intrinsic and newly recruited cells.
Figure 3 CCL2 overexpression induces GFP+ BMDC extravasation into mouse CNS parenchyma. Five million CD11b+ BMDCs were
injected into the left ventricles of rAAV9-CCL2 mice. Photomicrographs of GFP+ infiltrating cells in the cortex (A) and (B) and hippocampus
(C) and (D) are presented. Insets in (B) and (D) represent higher magnification of GFP+ cells. (E) The number of infiltrating GFP+ BMDCs was
determined by cell counting in both hippocampus and cortex. CCL2 overexpression in hippocampus resulted in significantly more GFP+ cells
than in the cortex in this cohort. (F) Representative data set from flow cytometry profile of one of six mice per group analyzed to detect the
GFP+ cells infiltrating the brain homogenate. The percentages of cells were derived from data gated on lower forward-scatter light characteristics
versus FITC fluorescence intensity. (G) Data analysis of 2,000 cells from flow cytometry where cells with fluorescence intensity greater than
1 × 104 were counted and graphed using GraphPad Prism 5 software (GraphPad Software). Student’s t-test, *P < 0.05, **P < 0.01. Scale bars
represents 200 μm and 20 μm.
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AAV9-mediated CCL2 overexpression induces protein
and mRNA changes in genes associated with
neuroinflammation
Next, we assessed the CCL2-induced production of cyto-
kines reported to be indicative of M1 vs M2 activation
states. Hippocampi from rAAV9-CCL2- and rAAV9-GFP
-injected animals (cohort 2) were homogenized and
processed as described above. We observed nine- and six-
fold increases in the levels of IL-6 and GM-CSF (Figure 8),
respectively, in the hippocampi of CCL2-treated mice (5.8 ±
1.9 pg/ml vs 7.5 ± 3.9 pg/ml) compared to GFP-injected
mice (0.5 ± 0.2 pg/ml vs 1.2 ± 0.4 pg/ml). In addition,
eotaxin 1 (CCL-11) levels were increased 2.5-fold in re-
sponse to CCL2 overexpression (13.9 ± 3.4 pg/ml vs 7.5 ±
0.8 pg/ml, P < 0.05, in CCL2-injected animals vs GFP con-
trol animals, respectively). Meanwhile, CCL2 overexpression
did not significantly increase the levels of the M1-related
cytokines TNF-α, IL-1β and IL-17, whereas levels of IL-
12p70 and IFN-γ were undetectable. In addition, mean
levels of M2-related cytokines IL-4, IL-10 and IL-13 were
slightly increased in the CCL2-injected mice but these
data did not reach statistical significance (26 ± 5.1 pg/ml,
12 ± 3.6 pg/ml and 392 ± 207 pg/ml, respectively) com-
pared to control animals (14 ± 5.6 pg/ml, 7.2 ± 3.0
pg/ml and 482 ± 396 pg/ml, respectively). In summary,
CCL2 overexpression in mice produced a unique pattern of
inflammatory signals, with significant inductions in GM-
CSF, eotaxin 1 and IL-6, at the time of investigation.
We used quantitative RT-PCR to investigate CCL2-
induced changes in the mRNA levels of gene transcripts
that are associated with M1 or M2 activation states [27,59].
We used the anterior cortex region of animals from both
groups of cohort 2 to identify the genes that were differen-
tially expressed. We used the rigorous criteria of qRT-PCR
described previously [65] to determine that 7 of 14 gene
transcripts were significantly changed by overexpression of
Figure 4 CD45 accumulation in the brain is driven by CCL2 overexpression. (A) through (D) Immunohistochemical staining for CD45
revealed significantly increased activation/recruitment of CD45+ macrophages in the cortex (B) and hippocampus (D) of rAAV9-CCL2-injected
animals, but not in the control group (A) and (C). CD45+ macrophages display various phenotypic morphologies in rAAV9-CCL2 animals (E) through
(H). Quantification of the percentage area containing positive CD45 immunostaining is presented for each brain region in (I) and (J) (mean ± SEM,
n = 6). Statistical analysis was performed using Student's t-test (**P < 0.01). Scale bars represent 200 μm (A), (B), (C) and (D) and 20 μm (E), (F), (G) and (H).
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CCL2 (Table 1). We showed a significant increase in gene
transcripts such as Arg-1, Chi3L3 (YM1) and EAR2 (2.4-,
2.7- and 3.8-fold increases, respectively). These genes and
their respective proteins are widely used as markers of M2
alternatively activated macrophages and are generally re-
sponsive to the effects of cytokines such as IL-4 and IL-13
[64]. Gene transcripts associated with M1 classically acti-
vated microglia were also induced. S100A8 and
S100A9 are two small calcium-binding proteins in-
creased during proinflammatory activity. The expression
of S100A8 was increased threefold in the cortex of CCL2-
overexpressing animals compared to controls. The expres-
sion of the Sirp1β transcript, a member of transmembrane
glycoproteins expressed in myeloid cells and associated
with phagocytosis [66], was strongly (17-fold) increased in
response to CCL2. Because CCL2 overexpression signifi-
cantly increased levels of eotaxin 1 protein, we investi-
gated the expression levels of other C-C motif ligands
with chemotactic activity. We found a 1.7-fold increase in
CCL24 (eotaxin 2), but not in CCL26 (eotaxin 3, Table 1),
compared to control tissue. Not all the genes related to
the M1 or M2 activation state of microglia were affected
by CCL2 (Table 1). For example, expression of iNOS,
which is involved in the M1 classical activation of micro-
glia, was not changed. Marco expression, another M1
marker, declined slightly, whereas the expression of
S100A9 RNA was unchanged, despite the increased pro-
tein observed by immunohistochemical analysis. These
findings suggest that the effect of CCL2 can be specific to
some of the gene transcripts, but not to all microglia-
related gene transcripts.
Discussion
Infiltration of peripheral macrophages into the CNS oc-
curs in small quantities, and it is not clear what role, if
any, they play in age-associated neurodegenerative disease.
Figure 5 MHCII activation is induced in the brains of CCL2-overexpressing mice. (A) through (D) Immunohistochemical staining for MHCII
showed that mononuclear cells/macrophages significantly increased MHCII expression following CCL2 overexpression. Images were collected from the
cortices and hippocampi of wild-type mice injected with either rAAV9-GFP (A) and (C) or rAAV9-CCL2 (B) and (D). MHCII+ cells displayed various phenotypic
morphologies, from rounded to ramified (arrow) and amoeboid (arrowhead) (E) through (H). Mean ± SEM percentage area for immunostaining of MHCII+
microglia in cortex and hippocampus are presented in (I) and (J). Student's t-test. (**P < 0.01, n = 6). Scale bars represent 200 μm and 20 μm.
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In addition, whether their effect is beneficial or pathological
appears to be dependent on the CNS insult (for review, see
[67]). Less attention has been focused on the responses of
resident brain microglia to CCL2. Consequently, we used
viral vectors to generate CCL2 overexpression in the adult
brain. Seven weeks after intracranial injection of rAAV-
CCL2, CCL2 was expressed at high levels in cortical and
hippocampal neurons. Previous work has documented
neuronal tropism for AAV vectors and long-term expression
[35,68]. In response, two markers of microglial activation,
CD45 and MHCII, were elevated around the site of injec-
tion. Both rounded and ramified morphologies were ob-
served. CCL2 also increased expression of markers
indicating both a proinflammatory M1 phenotype and an
alternative M2 phenotype. Increased staining was ob-
served for the M1 markers calgranulin B (S100A9) and
IL-1β, as well as for the M2-selective markers arginase 1
and YM1. In addition, cytokine/chemokine production
and gene expression data confirm that both M1 and M2
marker RNAs and proteins were induced. Together, these
results indicate that CCL2 induces a unique profile of acti-
vation markers, thereby influencing the cerebral inflam-
matory environment. The dichotomy between M1 and
M2 activation states appears blurry and may not be a use-
ful categorization of microglial activation.
Microglia populate the CNS during early embryo-
genesis, whereas monocytes circulate in the blood, pa-
trolling the environment. In untreated normal mice,
monocytes are generally unable to enter the brain,
which is anatomically separated from the periphery by
the blood-brain barrier (BBB) [40,69]. The roles of
peripheral monocyte subsets and their extravasation
vary in different disease models and different organs
[70]. Identification of monocyte infiltration has been
greatly improved by the development of GFP/RFP
knock-in reporter mice [71-73] and the use of GFP-
labeled bone marrow chimeras following X-irradiation.
However, potential effects of radiation on the brain
microenvironment, including microglial activation,
BBB integrity and promoting myeloid cell engraftment
have been raised [74]. To track the rate of monocyte
infiltration in vivo, we used the transfer of GFP+
bone marrow cells positively selected for the CD11b
Figure 6 Induction of microglial markers of classical activation
(M1) and alternative activation (M2) following rAAV9-CCL2
transduction. Mice which received control GFP viral vector (A),
(D), (G) and (J) or mice overexpressing CCL2 (B), (C), (E), (F), (H), (I),
(K) and (L) were stained using immunohistochemistry for microglial
markers representing the M1 activation state: calgranulin B
(Calg.B or S100-A9: (A), (B) and (C)) and IL-1β ((D), (E) and (F)); or
the M2 activation state: arginase 1 (Arg-1: (G), (H) and (I)) and YM1
(J), (K) and (L). (C), (F), (I) and (L) are images of different microglial
morphology stained for each marker. Scale bar is 20 μm.
Figure 7 Recruited BMDCs express some markers in common
with microglia. (A) through (C) show immunofluorescent staining
of YM1 (A), blue on a recruited GFP BMDC (B), green in the blood
vessels surrounding the hippocampus of a CCL2-overexpressing animal.
(D) through (F) In contrast, recruited cells (GFP, E) did not express
MHCII (D, blue). Merged images of each respective double-stain are
shown in (C) and (F). Scale bar represents 10 μm.
Figure 8 Induced protein expression profile following CCL2
overexpression. A series of cytokine and chemokine protein
expression levels were measured using the mouse multiplex assay in
hippocampal tissue after rAAV9-CCL2 transduction. Cytokine levels
are expressed as fold changes relative to the GFP control animals
(n = 6). *P < 0.05, **P < 0.01.
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monocytic subset. We have previously shown that this
monocytic subset migrates into APP/PS1 mouse brain
in the absence of X-irradiation and become localized
around amyloid plaques [40]. In the present study, we
have shown that CCL2 was able to promote the ex-
travasation of blood-derived GFP monocytes into
wild-type mouse CNS. Immunohistochemistry re-
vealed GFP+ cells in the parenchyma of the ipsilateral
hemisphere in the vicinity of the injection site as well
as in perivascular areas. These cells were round with
a diameter approximating 10 μm, consistent with the
size expected for monocytes. Stereological counts
showed significantly more GFP+ cells in hippocampus
than in anterior cortex. No GFP+ cells were observed
in the contralateral hemisphere (cohort 1) in the ab-
sence of CCL2 overexpression. We also isolated
single-cell suspensions from brain homogenates from
cohort 2 for flow cytometry. GFP+ cells could be
identified only in CCL2-treated brains. It is likely that
neurons are not captured by this isolation procedure.
Nineteen percent of the recovered cells were recruited
GFP+ in the brains of CCL2-treated mice. Our data
are in agreement with other findings showing that
CCL2 is sufficient for recruiting blood-borne cells to
sites of brain injury [75]. It is likely that the CCL2
levels achieved in this model may also be reached
during periods of CNS inflammation. This model may
be a useful experimental system to analyze the effects
of CCL2 on extravasation of blood-borne macrophages
across the BBB.We used immunofluorescence to deter-
mine whether recruited GFP+ cells express markers in
common with microglia. We observed colocalization of
GFP with YM1, but not with MHCII. Thus, it is not pos-
sible to discriminate resident microglia from infiltrating
monocytes with the microglial markers in common use at
present. The extent to which infiltrating cells can enter the
brain in disease states and differentiate into macrophages
and/or microglia is unclear. Future experiments could
examine longer time periods to determine patterns of dif-
ferentiation of the monocytes entering the CNS in re-
sponse to CCL2.
Several transgenic CCL2 mouse models have been de-
veloped in an effort to understand the chemotactic and
recruitment properties mediated by brain CCL2 in vivo.
CCL2 expressed under the control of the myelin basic
promoter caused prominent mononuclear cell infiltra-
tion in the brain [3,76]. These cells were characterized
as F4/80, Mac-1 and CD45 leukocytes and were located
largely in the perivascular space. Inflammatory stimuli
(lipopolysaccharide (LPS) and pertussis toxin) promoted
parenchymal infiltration of leukocytes. Similarly, the glial
fibrillary acidic protein (GFAP) promoter was used to
overexpress CCL2 in another line of mice. These mice
developed age-dependent accumulation of leukocytes in
the perivascular space and increased expression of CD45
[77]. Inflammatory signals or viral infection resulted in
more severe disease and/or more rapid onset of symp-
toms [33,78,79]. Our data demonstrate that CCL2
expressed under the chicken β-actin promoter and intro-
duced into the adult CNS via AAV9 resulted in paren-
chymal recruitment of GFP+ BMDCs, as well as local
presence of ramified and amoeboid-activated cells ex-
pressing MHCII and CD45.
In our model, activated microglia displayed both M1 and
M2 phenotypes in response to overexpression of CCL2, at
least at the time of this investigation. On the basis of pub-
lished work, we believe the CCL2 was overexpressed for
the majority of the 7-wk treatment period. Other authors
have demonstrated that a transgenic mouse that expressed
CCL2 under the GFAP promoter developed pertussis-
induced reversible inflammatory encephalopathy and that
CCL2 directed a Th1-biased inflammatory reaction, as
shown by high levels of TNF-α, INFγ and IL-2 in the CNS.
In contrast, mice lacking CCL2 exhibit decreased severity
of experimental autoimmune encephalomyelitis with di-
minished Th1 cytokine secretion in the CNS [10,33,77,80].
Other research highlights the importance of CCL2 in Th2-
selective activation [32,81]. In a pulmonary granuloma
model, overexpression of mouse CCL2 via recombinant
adenovirus serotype 5 differentially altered the outcome of
the immune responses toward the Th2 phenotype and was
accompanied by increased production of IL-10 and IL-13
[82]. However, we found that the levels of proinflammatory
cytokines in the hippocampi of CCL2 mice either were not
significantly increased (TNF-α, IL-1β and IL-17) or were
undetectable (IFNγ and IL-12p70). In addition, the levels
of anti-inflammatory cytokines such as IL-4, IL-10 and IL-
13 were slightly but not statistically significantly increased,
suggesting a modest impact of CCL2 on the M2 activation
state. Instead, CCL2 induced a pattern of cytokine induc-
tion that was unique and not completely consistent with
either an M1 or an M2 pattern. We observed elevations in
the levels of IL-6, GM-CSF and CCL11 (eotaxin 1) follow-
ing CCL2 overexpression.
Using qRT-PCR, immunohistochemistry or multiplex
assay, we have shown that CCL2 upregulated the levels of
genes or gene products associated with both M1 and M2
microglial activation. For example, mRNA levels for arginase
1 (Arg1), chitinase 3-like-3 (YM1), eosinophil-associated
ribonuclease A family (Ear-2) and chemokine 24 (CCL24)
were significantly increased. Arg1 and YM1 protein were
also elevated as assessed by immunohistochemistry. These
observations are consistent with an M2 polarized activation
response [59,64]. Other genes whose mRNA or protein ex-
pression was increased significantly included the M1-
associated markers S100A8, S100A9, IL-1β and Sirpβ.
S100A8 and S100A9 are putative ligands of the receptor for
advanced glycation end products [49], a proinflammatory
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receptor that has been implicated in many chronic inflam-
matory diseases, including AD [83,84]. Other markers of
M1 activation, such as TNF-α, iNOS and Marco, were not
significantly elevated.
The phagocytic activity of microglia expressing S100A8
and Sirpβ proteins have been reported in acute and chronic
inflammation [46,85]. It is still not clear whether CCL2 acts
as a modulator of resident microglial phagocytosis or as a
chemoattractant for peripheral macrophages to infiltrate the
brain and accelerate clearance of pathological aggregates.
Recent evidence derived using genetically modified animal
models of amyloid deposition suggests that infiltrating mac-
rophages reduce amyloid deposits [15-18,86,87]. Other stud-
ies have suggested a role of CCL2 in accelerating the
development of oligomeric and soluble amyloid-β levels
[19,88,89]. Our data demonstrate that CCL2 not only was
able to activate resident microglia but also induced gene ex-
pression linked to both the M1 and M2 activation pathways.
The presence of both classes of markers could demon-
strate a continuum of microglial activation. For in-
stance, increases in mRNA levels for markers of both
M1 and M2 activation in animal models of AD have
been reported, suggesting heterogenicity of these cells
[27,90]. Induction of “classical” activation of microglia
has been proven to be beneficial in the clearance of
amyloid-β pathology [91]. On the other hand, a re-
cent report by Heneka and collaborators demonstrated
that NLRP3 inflammasome deficiency skewed microglial
activation toward a M2 signature but also resulted in
decreased amyloid-β deposits [92]. Meanwhile, activa-
tion of microglia via LPS- or CX3CR1-deficient
microglia significantly induced tau pathology, possibly
via IL-1/p38MAPK signaling pathway activation [93,94].
These findings underscore the need for further examin-
ation of the functional properties of M1 vs M2 microglial
activation. Although we did not investigate how this in-
flammation correlates with the pathology related to a spe-
cific neurological disease, the role of CCL2-mediated
inflammation in pathological settings needs to be clarified.
Interestingly, increased CCL2 levels have been found in
the brain, serum and cerebrospinal fluid of AD patients
[20,95]. Further, in a recent study, Westin et al. reported
that the CCL2 levels in the cerebrospinal fluid are corre-
lated with faster cognitive decline in patients with early-
stage AD [96]. Changes in the levels of CCL2 and its
CCR2 receptor have been found in the brain tissue of pa-
tients with trauma, prion disease, cerebral malaria, HIV
dementia, Parkinson’s disease and multiple sclerosis (see
[67] for review).
In conclusion, our study confirms the role of CCL2 in
promoting the activation of several molecules that may
participate in altering the immune response. The finding
that CCL2 can influence the direction of an immune re-
sponse further indicates the complexity of inflammatory
responses and the importance of this molecule. Our data
suggest an important role of CCL2 in activating micro-
glia and defining the CNS inflammatory milieu. It also
highlights the use of gene therapy approaches to investi-
gate the role of blood-borne myeloid precursors in CNS
diseases.
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